Can high bone turnover markers identify osteopenic postmenopausal women at risk of future fracture?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 8, 2007, Pages 570-571

  Reid, David M ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Bisphosphonate; Bone turnover marker; Cost effectiveness; Fracture

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID;

ADULT; ADVERSE OUTCOME; AGED; BONE RADIOGRAPHY; BONE TURNOVER; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; FEMALE; FOREARM FRACTURE; FRACTURE; HIGH RISK POPULATION; HIP FRACTURE; HIP RADIOGRAPHY; HUMAN; NOTE; OSTEOPENIA; OUTCOME ASSESSMENT; POPULATION RISK; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; VERTEBRA FRACTURE;

EID: 34447639102     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0560     Document Type: Note

References (5)

1. Bauer DC et al. (2006) Pretreatment levels of bone turnover and the anti-fracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res 21: 292-299
2. Cummings SR et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077-2082
3. McClung MR et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333-340
4. Chesnut CH III et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241-1249
5. McCloskey EV et al. (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22: 135-141